SavedAdd your journal

Journals / Anadolu Kliniği Tıp Bilimleri Dergisi / 2020 / Cilt: 25 - Sayı: 3

An Investigation of the Relationship between SIRT1 Gene Polymorphisms and Parkinson’s Disease

SIRT1 Gen Polimorfizmleri ve Parkinson Hastalığı Arasındaki İlişkinin Araştırılması

Esra Acıman Demirel
Sevim Karakaş Çelik
Meryem Kuşçu
Esra Ermiş
Pages
230–236
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Discussion and Conclusion: Our findings indicated that the SIRT1 gene polymorphisms investi- gated did not play a predisposing role in the development of Parkinson’s disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Parkinson’s disease is a disorder caused by insufficient dopamin production due to the loss of dopaminergic neurons concentrated in the substantia nigra of the brain.
📊
Key Findings & Data:The Sirtuin1 (SIRT1) gene, shown to protect cells against oxidative stress, has been reported to be associated with predis- position to Parkinson’s disease.
💡
Conclusion & Impact:Discussion and Conclusion: Our findings indicated that the SIRT1 gene polymorphisms investi- gated did not play a predisposing role in the development of Parkinson’s disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Parkinson’s disease is a disorder caused by insufficient dopamin production due to the loss of dopaminergic neurons concentrated in the substantia nigra of the brain. Oxidative stress and mitochondrial dysfunction play a central role in the pathogenesis. The Sirtuin1 (SIRT1) gene, shown to protect cells against oxidative stress, has been reported to be associated with predis- position to Parkinson’s disease. In this study, we aimed to investigate the relationship between Parkinson’s disease and the SIRT1 gene polymorphisms rs7895833 and rs2273773. Materials and Methods: The study included 40 patients with Parkinson’s disease (the patient group) and 50 healthy individuals (the control group). The polymerase chain reaction with confronting two-pair primers (PCR-CTPP) and polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) methods were used for the rs7895833 and rs2273773 poly- morphisms, respectively. Results: For the rs7895833 polymorphism, the genotype distribution for the patient and control groups respectively was as follows: AA (62.5%–53.1%), AG (27.5%–40.8%), GG (10.0%–6.1%). For the rs2273773 polymorphism, the genotype frequencies for the patient and control groups were as follows: TT (90.0%–98.0%), CT (10.0%–2.0%). No statistically significant difference was found between the patient and control groups in terms of rs2273773 and rs7895833 polymorphisms (p>0.05). Discussion and Conclusion: Our findings indicated that the SIRT1 gene polymorphisms investi- gated did not play a predisposing role in the development of Parkinson’s disease.

Özet

Amaç: Parkinson hastalığı, beyinde substansiya nigrada yoğunlaşmış dopaminerjik nöronların kaybı nedeniyle yeterince dopamin üretilememesi sonucu ortaya çıkan bir hastalıktır. Oksidatif stres ve mitokondriyal disfonksiyon patogenezde merkezî bir rol oynar. Hücreleri oksidatif strese karşı koruduğu tespit edilen Sirtuin1 (SIRT1) geni Parkinson hastalığına yatkınlıkla ilişkilendiril- miştir. Bu çalışmada SIRT1 geni rs7895833 ve rs2273773 polimorfizmleri ile Parkinson hastalığı arasındaki ilişkiyi araştırmak amaçlanmıştır. Gereç ve Yöntemler: Çalışmamız 40 Parkinson hastası (hasta grubu) ile 49 sağlıklı birey (kont- rol grubu) içerdi. rs7895833 polimorfizmi için polimeraz zincir reaksiyonu–confronting two-pair primers (PCR-CTPP) yöntemi, rs2273773 polimorfizmi içinse polimeraz zincir reaksiyonu–rest- riksiyon parça uzunluk polimorfizmi (PCR-RFLP) yöntemi kullanıldı. Bulgular: rs7895833 polimorfizmi için sırasıyla hasta ve kontrol gruplarındaki genotip dağılımı AA (%62,5–%53,1), AG (%27,5–%40,8), GG (%10,0–%6,1) şeklindeydi. rs2273773 polimorfizmi için ise hasta ve kontrol grubu genotip frekansları şu şekildeydi: TT (%90,0–%98,0), CT (%10,0– %2,0). rs2273773 ve rs7895833 polimorfizmleri bakımından hasta ve kontrol grupları arasında istatistiksel olarak anlamlı bir fark tespit edilmedi (p>0,05). Tartışma ve Sonuç: Bulgularımız incelenen SIRT1 gen polimorfizmlerinin Parkinson hastalığı ge- lişiminde zemin hazırlayıcı bir rol oynamadığına işaret etmektedir.

🔖

Cite This Article

Demirel, E. A., Çelik, S. K., Kuşçu, M., Ermiş, E. (2022). An Investigation of the Relationship between SIRT1 Gene Polymorphisms and Parkinson’s Disease. Anadolu Kliniği Tıp Bilimleri Dergisi, Cilt: 25 - Sayı: 3, 230–236. https://ajindex.com/articles/437641

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Braak H, Tredici KD. Invited article: nervous system pathology in sporadic Parkinson disease. Neurology. 2008;70:1916–25
  2. Devine MJ, Gwinn K, Singleton A, Hardy J. Parkinson’s disease and asynuclein expression. Mov Disord. 2011;26:2160–8
  3. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transciptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403:795–800
  4. Landry J, Sutton A, Tafrov ST, Heller RC, Stebbins J, Pil- lus L, ve ark. The silencing protein SIR2 and its homo- logs are NAD-dependent protein deacetylases. Proc Natl Acad Sci U S A. 2000;97:5807–11
  5. Smith JS, Brachmann CB, Celic I, Kenna MA, Mu- hammad S, Starai VJ, ve ark. A phylogenetically con- served NAD+-dependent protein deacetylase activity in the Sir2 protein family. Proc Natl Acad Sci U S A. 2000;97:6658–63
  6. Nakagawa T, Guarente L. Sirtuins at a glance. J Cell Sci. 2011;124:833–8
  7. Morris BJ. Seven sirtuins for seven deadly diseases of aging. Free Radic Biol Med. 2013;56:133–71
  8. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, ve ark. Negative control of p53 by Sir2 alpha promotes cell survival under stress. Cell. 2001;137:137–48
  9. Maiese K, Chong ZZ, Shang YC. OutFOXOing disea- se and disability: the therapeutic potential of targeting FOXO proteins. Trends Mol Med. 2008;14:219–27
  10. Maiese K, Chong ZZ, Shang YC, Hou J. A “FOXO” in sight: targeting Foxo proteins from conception to cancer. Med Res Rev. 2009;29:395–418
  11. Hasegawa K, Wakino S, Yoshioka K, Tatematsu S, Hara Y, Minakuchi H, ve ark. Sirt1 protects againts oxidative stress-induced renal tubular cell apoptosis by the bidi- rectional regulation of catalase expression. Biochem Bi- ophys Res Commun. 2008;372:51–6
  12. Chong ZZ, Lin SH, Li F, Maiese K. The sirtuin inhibi- tor nicotinamide enhances neuronal cell survival during acute anoxic injury through AKT, BAD, PARP, and mi- tochondrial associated “anti-apoptotic” pathways. Curr Neurovasc Res. 2005;2:271–85
  13. Chong ZZ, Maiese K. Enhanced tolerance against early and late apoptotic oxidative stress in mammalian neu- rons through nicotinamidase and sirtuin mediated path- ways. Curr Neurovasc Res. 2008;5:159–70
  14. Donmez G, Arun A, Chung CY, McLean PJ, Lindquist S, Guarente L. SIRT1 protects against a-synuclein agg- regation by activating molecular chaperones. J Neurosci. 2012;32:124–32
  15. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–42
  16. Donmez G, Outeir